Nutlin-3a

For research use only. Not for use in humans.

目录号:S8059 别名: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a是Nutlin-3的活性对映体,抑制p53/MDM2相互作用,无细胞试验中IC50为90 nM。

规格 价格 库存 购买数量  
RMB 1624.68 现货
RMB 5480.74 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Nutlin-3a发表文献37篇:

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述 Nutlin-3a是Nutlin-3的活性对映体,抑制p53/MDM2相互作用,无细胞试验中IC50为90 nM。
特性 高度选择性的MDM2抑制剂与对MDMX低得多的效果。对含野生型p53的肿瘤最有效。
靶点
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
体外研究

Nutlin-3α从MDM2蛋白的结合口袋置换p53,由此将p53从抑制和蛋白酶体降解状态释放出来,从而导致诱导其下游靶点,细胞周期停滞和细胞凋亡。七天孵育10 μM nutlin-3a导致了NIH3T3细胞的生长抑制达90%以上。[1] Nutlin-3α稳定并激活p53基因,以剂量依赖性的方式诱导p21的表达。[1] Nutlin-3A有效地减少S期细胞至0.2-2%,并增加了G1-和G2/M期细胞。[1] 在40小时后,Nutlin-3a诱导约60% SJSA-1和MHM细胞的凋亡,而到60小时后,凋亡细胞分别达到85%和65%。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NU\UcmdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNkGyN|ch|ryP NXyyPJQzW0GQR1XS
H4 M1G3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LN[mlEPTB;MD62OlI5KM7:TR?= M{\MNHNCVkeHUh?=
PA-1 NXfRcXFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HxbWlEPTB;MD64O|A6PiEQvF2= MoX0V2FPT0WU
NKM-1 M{TROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDoOYRKSzVyPUGuNFQ6OzFizszN MlX0V2FPT0WU
NEC8 NWfPZ25MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO2[GNKSzVyPUGuNlE2PzJizszN NUHwbWRIW0GQR1XS
EoL-1-cell NEewWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwMk[3NFEh|ryP MWnTRW5ITVJ?
K5 NH\rUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfKTXVmUUN3ME2xMlQzODd{IN88US=> NFTvS5RUSU6JRWK=
QIMR-WIL M4q4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfhfItKSzVyPUGuOlA5PTRizszN MlTxV2FPT0WU
MOLT-16 NV:xXng2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwN{i2NFQh|ryP MXzTRW5ITVJ?
CHP-212 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nKe2lEPTB;MT64NVM3QSEQvF2= M1rXe3NCVkeHUh?=
CTB-1 NVfBblZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwMEKyOFYh|ryP MnjQV2FPT0WU
MOLT-4 NWH4[Hp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXKOZBJUUN3ME2yMlMzQDV|IN88US=> M{iwfXNCVkeHUh?=
A101D NITaV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3OpZKSzVyPUKuN|UxOSEQvF2= MoSwV2FPT0WU
DOHH-2 NWLnSoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULaZnJMUUN3ME2yMlQzOjd7IN88US=> NInxVY9USU6JRWK=
ES4 M4X6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPTTWM2OD1{LkSzNVU2KM7:TR?= M13nTnNCVkeHUh?=
SW780 NU\nUmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG0c5FIUUN3ME2yMlUxQDh|IN88US=> NHfQVoZUSU6JRWK=
VA-ES-BJ M{XvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG2TWM2OD1{LkW0NVEh|ryP M2r3VHNCVkeHUh?=
RPMI-8866 NHn3cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\hSWlEPTB;Mj61OlIyPCEQvF2= MV7TRW5ITVJ?
ML-2 M4O5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQdpNKSzVyPUKuOVY2PzZizszN NHP1XGlUSU6JRWK=
MSTO-211H NXraWmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C3UGlEPTB;Mj61O|Q2OSEQvF2= NIrmemdUSU6JRWK=
JVM-3 NUTLTFExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJwNUmzNlQh|ryP NE\5fHdUSU6JRWK=
A3-KAW NITKUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD0U4VIUUN3ME2yMlYyQDF6IN88US=> Mkj4V2FPT0WU
DK-MG NGrBXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJwNkK0O|Eh|ryP M1HOPXNCVkeHUh?=
LNCaP-Clone-FGC MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTGTWM2OD1{Lk[0N|E5KM7:TR?= MkXkV2FPT0WU
HT-144 NGD1PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PUZ2lEPTB;Mj62OFU4PyEQvF2= MkntV2FPT0WU
NB69 Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvYTWM2OD1{Lk[1N|M1KM7:TR?= NIC1VHlUSU6JRWK=
A172 NILPZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu0TWM2OD1{Lk[3OVg5KM7:TR?= M3WxZnNCVkeHUh?=
RS4-11 NUHmblB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nWRmlEPTB;Mj63NlQxPyEQvF2= MmTNV2FPT0WU
DU-4475 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\3Z4VKSzVyPUKuO|k2ODJizszN MorDV2FPT0WU
SJSA-1 NVyxd5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PlV2lEPTB;Mj64NlU2PiEQvF2= NI\KO|ZUSU6JRWK=
BV-173 M3jMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPRTmNKSzVyPUKuPFQ1OzlizszN NV\ENmR{W0GQR1XS
U-2-OS M1:1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jVfGlEPTB;Mj65NVA4KM7:TR?= Moj0V2FPT0WU
CHP-134 M{LWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfqT2hKSzVyPUKuPVM5QDJizszN MUPTRW5ITVJ?
D-502MG MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DlfmlEPTB;Mj65O|E2PCEQvF2= MmnTV2FPT0WU
KS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnFcXpKSzVyPUOuNFE3OjNizszN NY\0RmU2W0GQR1XS
A204 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H3eGlEPTB;Mz6wOVU5QCEQvF2= M3faZnNCVkeHUh?=
KGN MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLEVndKUUN3ME2zMlA5PDl4IN88US=> M{OydnNCVkeHUh?=
NCI-H292 M3W0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwMUKwNlgh|ryP MUnTRW5ITVJ?
CAKI-1 M{f6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi1XItZUUN3ME2zMlEzPjl2IN88US=> MUjTRW5ITVJ?
C2BBe1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNwMUewNlYh|ryP MYfTRW5ITVJ?
NB10 M{fNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrvTWM2OD1|LkKwPVY3KM7:TR?= MY\TRW5ITVJ?
MHH-NB-11 MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwMk[4Nlch|ryP MlnuV2FPT0WU
NCI-SNU-1 NULONoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq1NmJKSzVyPUOuNlc5PDNizszN MkTYV2FPT0WU
HCT-116 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSwTWM2OD1|LkOwN|M2KM7:TR?= Mny3V2FPT0WU
G-401 MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[0TJV3UUN3ME2zMlM3OzJ{IN88US=> MXPTRW5ITVJ?
MN-60 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XT[GlEPTB;Mz60OFA6OiEQvF2= NXfDe21JW0GQR1XS
SW982 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vaTGlEPTB;Mz61NFg1QCEQvF2= NULRO21OW0GQR1XS
RKO NF23T5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS4TWM2OD1|LkWzPVM3KM7:TR?= NFqwVotUSU6JRWK=
D-283MED M3;LUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j2[WlEPTB;Mz61O|k5PiEQvF2= MonCV2FPT0WU
LB996-RCC MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojHTWM2OD1|Lk[yOVU5KM7:TR?= M4n0dHNCVkeHUh?=
A549 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNwNkO1OVIh|ryP M3\PcHNCVkeHUh?=
LB2241-RCC NWLEco5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrITWM2OD1|Lk[1O|A5KM7:TR?= MUjTRW5ITVJ?
SK-HEP-1 MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfuTWM2OD1|Lke0Nlk4KM7:TR?= M3HofnNCVkeHUh?=
G-402 NELuO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYeyTJlkUUN3ME2zMlgxQDN{IN88US=> NGLKW|lUSU6JRWK=
GOTO MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNwOESzN|Mh|ryP MUHTRW5ITVJ?
LOXIMVI NF3T[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTNwOEW2O|Uh|ryP NWPDe|hSW0GQR1XS
NH-12 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjwTWM2OD12LkCxPVU6KM7:TR?= M3q2ZXNCVkeHUh?=
CTV-1 NV23eGJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Lyd2lEPTB;ND6wO|k4OyEQvF2= NVvHV5VsW0GQR1XS
CP50-MEL-B M1LjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHqT2hKSzVyPUSuNlQ{QTJizszN NVT1dpU3W0GQR1XS
RH-18 NYLTb4E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrqZnBKSzVyPUSuNlc4ODZizszN MY\TRW5ITVJ?
NB17 M4XFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX2OVZMUUN3ME20MlMyPzZ6IN88US=> M{j5VnNCVkeHUh?=
A375 NEi4ZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD2O3VyUUN3ME20MlM{PTJ2IN88US=> NXnEeGFDW0GQR1XS
IST-MES1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC1XYRKSzVyPUSuOFE1OTFizszN MoPWV2FPT0WU
MZ2-MEL NXHPdItGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwNUCxOVUh|ryP MXHTRW5ITVJ?
CAL-54 NYjRfWc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvNVIJKSzVyPUSuOVMxOTlizszN M4n4c3NCVkeHUh?=
NCI-H28 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi5THFLUUN3ME20MlYzPzF5IN88US=> NXz3SVUzW0GQR1XS
D-247MG MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXiTWM2OD12Lke1NFczKM7:TR?= NF7Db|BUSU6JRWK=
NCI-H460 NV3EXWpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;zXmlEPTB;ND65NVEzPyEQvF2= NWDNfXlVW0GQR1XS
MCF7 NHrzSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PK[mlEPTB;NT60OFI1PCEQvF2= M4e4XXNCVkeHUh?=
697 M3PUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7UTWM2OD13LkS0OVUh|ryP NWnGOoVHW0GQR1XS
ONS-76 NUD1cZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTVwNUewNFkh|ryP MXTTRW5ITVJ?
C32 M3fMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL3UXpTUUN3ME21MlYxODJ7IN88US=> MX\TRW5ITVJ?
OS-RC-2 M3LlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTVwN{O4PFch|ryP Mn3MV2FPT0WU
MEL-HO MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknTTWM2OD13Lki1OlY4KM7:TR?= MYPTRW5ITVJ?
LoVo M2jZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTZwMEG2NlQh|ryP NE\uUmJUSU6JRWK=
AGS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTZwMUS4Nlgh|ryP NEKwWodUSU6JRWK=
GI-ME-N MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnwVJdKSzVyPU[uNlI1OjFizszN MUHTRW5ITVJ?
H-EMC-SS M17QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZwM{i2JO69VQ>? M4DPfnNCVkeHUh?=
RVH-421 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTZwNEK0Nlgh|ryP NYP4d5I5W0GQR1XS
SW954 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTZwNUW1O|Ih|ryP M3K5XnNCVkeHUh?=
NB5 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H4PWlEPTB;Nj61OlE5OyEQvF2= NU\hZ4V7W0GQR1XS
NCI-H2122 NVXjfZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jZUmlEPTB;Nj61PFc6OyEQvF2= NFXKS2ZUSU6JRWK=
AM-38 NHLQUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjSWVBLUUN3ME22Mlc2PjN7IN88US=> M3r0TnNCVkeHUh?=
KNS-81-FD MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjzTWM2OD14Lke2OFk1KM7:TR?= M{fUWnNCVkeHUh?=
LS-513 M33Rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTpTWM2OD14Lke5NFI3KM7:TR?= M2\DU3NCVkeHUh?=
A427 NHm1TWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzF[|dKSzVyPU[uPFc5OjlizszN MmnWV2FPT0WU
WM-115 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O0VmlEPTB;Nj65N|I{KM7:TR?= MX\TRW5ITVJ?
COLO-829 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7NT4NKSzVyPUeuNlQyQDhizszN MV\TRW5ITVJ?
NCI-H1650 NFv4XHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTdwM{myNlgh|ryP NX\IPVJiW0GQR1XS
NCI-H358 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfDXJVKSzVyPUeuOFQ5PzlizszN NV;O[ldRW0GQR1XS
HT-1080 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTdwNEiyOVQh|ryP M{X0d3NCVkeHUh?=
HCC2218 NUDRPYJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojQTWM2OD15Lk[yPVch|ryP NUfqcHl3W0GQR1XS
NCI-H661 M{PTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHzVJNKSzVyPUeuPFcxPjlizszN MoPyV2FPT0WU
KM-H2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHDN4pKSzVyPUeuPFg3QTRizszN NH7He3BUSU6JRWK=
RPMI-2650 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH20NFZKSzVyPUeuPVQ1OTRizszN MVzTRW5ITVJ?
NCI-H226 NIfKRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7uTWM2OD16LkKxNVIzKM7:TR?= Ml3KV2FPT0WU
MKN45 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;nTWM2OD16LkK2OlAzKM7:TR?= MUnTRW5ITVJ?
D-392MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3mTWM2OD16LkWyO|IzKM7:TR?= M4K4RnNCVkeHUh?=
RCC10RGB MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRThwOE[2PVUh|ryP MWfTRW5ITVJ?
CAL-51 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfRWHVKSzVyPUmuNVAzPTFizszN NETMfXZUSU6JRWK=
COLO-678 NXLTR2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\SW|ZKSzVyPUmuN|I5OTFizszN M2D1PHNCVkeHUh?=
SK-MEL-24 NUfBOJpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvtfVdJUUN3ME25MlU2QDV4IN88US=> NFjyOHlUSU6JRWK=
SK-MEL-30 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n3UWlEPTB;OT65OFQ4PiEQvF2= MVXTRW5ITVJ?
MMAC-SF M{LBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzP[lVKSzVyPUGwMlM6PjFizszN MkPBV2FPT0WU
NTERA-S-cl-D1 M4fWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfZTWM2OD1zMD62OVA5KM7:TR?= MXHTRW5ITVJ?
NB12 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLse2U6UUN3ME2xNU42ODNizszN NGi4WW5USU6JRWK=
UACC-257 NVrkTJdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDpV|ZRUUN3ME2xNU45Pjl3IN88US=> Mn7VV2FPT0WU
LAN-6 NETxSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX5VohxUUN3ME2xNU46QTJ6IN88US=> M4XNcnNCVkeHUh?=
SW1573 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF{LkOwPFYh|ryP MXnTRW5ITVJ?
NMC-G1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\GTWM2OD1zMj60NVc2KM7:TR?= NFraNYZUSU6JRWK=
SHP-77 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fnPWlEPTB;MUKuOVU4PCEQvF2= NUKwfoQyW0GQR1XS
IGROV-1 M2HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO5TWM2OD1zMj62OVc{KM7:TR?= NWnPb2JDW0GQR1XS
22RV1 NVf5NZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXCXIdzUUN3ME2xNk45ODV7IN88US=> NYnke|FEW0GQR1XS
SK-MEL-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ibGlEPTB;MUOuN|k4OyEQvF2= NX2wOItuW0GQR1XS
NCI-H1563 M{Pj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq1XFJKSzVyPUGzMlQzODJizszN MkLFV2FPT0WU
IGR-1 NYXCW2ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnGTWM2OD1zND6wN|Q4KM7:TR?= M1HHcHNCVkeHUh?=
EW-3 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7JeVBrUUN3ME2xOE4yPjN7IN88US=> NWjt[HEzW0GQR1XS
JEG-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXrcHY5UUN3ME2xOE41QTV|IN88US=> MlXRV2FPT0WU
ES3 M1u2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETifZZKSzVyPUG0MlY2PjJizszN MV;TRW5ITVJ?
MDA-MB-175-VII MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjYeHYzUUN3ME2xOE44OTFzIN88US=> M1v4c3NCVkeHUh?=
P30-OHK M1;3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP2ZZdwUUN3ME2xOU4xPDl4IN88US=> Mn24V2FPT0WU
GP5d NYjJVZFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LrVmlEPTB;MUWuNVQ3PiEQvF2= NWXISJRzW0GQR1XS
HMV-II NIPNbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq1dI1SUUN3ME2xOU4{OzN|IN88US=> NEnyRXVUSU6JRWK=
COLO-679 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H3SGlEPTB;MUWuOVAyKM7:TR?= NGflWWVUSU6JRWK=
JAR NGPnfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3mxUmlEPTB;MUWuO|IxPSEQvF2= MW\TRW5ITVJ?
NCI-H1666 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTKUZhJUUN3ME2xOU46Ozl7IN88US=> M3jie3NCVkeHUh?=
SW48 M1rteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvJ[2tEUUN3ME2xOU46PTF4IN88US=> NHvFdolUSU6JRWK=
NCI-H720 NHrvVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\xXGlEPTB;MUWuPVk5QSEQvF2= NH3GZYhUSU6JRWK=
HT-1197 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Swd2lEPTB;MU[uNFM2OiEQvF2= NF\1dHhUSU6JRWK=
HL-60 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF4LkCzPFQh|ryP MX\TRW5ITVJ?
BEN Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF4LkW2N|gh|ryP MlXKV2FPT0WU
HAL-01 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\VS2lEPTB;MU[uPFkxQSEQvF2= M4W4eHNCVkeHUh?=
SW900 NWXOU2ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjBUGVKSzVyPUG2MlkyOzJizszN MWXTRW5ITVJ?
SBC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlyzTWM2OD1zNz61OFI6KM7:TR?= M1jSSnNCVkeHUh?=
SH-4 NHS5bYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD4Roh5UUN3ME2xO{42QDRzIN88US=> M17Pc3NCVkeHUh?=
UACC-62 M2PmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF5Lke2N|ch|ryP NGrKV|hUSU6JRWK=
BHT-101 M1;Zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHzRWJKSzVyPUG5Mlg4ODVizszN M4DQ[XNCVkeHUh?=
DB MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzYTnB3UUN3ME2yNU42PjR7IN88US=> M3OxSXNCVkeHUh?=
SK-MEL-1 M{LXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LqNmlEPTB;MkGuOVg4OiEQvF2= NUPmcpNqW0GQR1XS
NCI-H747 M1z1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDFWlRKSzVyPUKyMlc{PzlizszN M4fHSXNCVkeHUh?=
SK-LU-1 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7vTVJzUUN3ME2yN{4{PTJ2IN88US=> MVHTRW5ITVJ?
KG-1 M4TaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvLWIZKSzVyPUKzMlQ6PDZizszN NYXGUXh4W0GQR1XS
LXF-289 M4TMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\MTWlEPTB;MkOuO|E1KM7:TR?= MnnVV2FPT0WU
HCC1954 NUPzUZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ey[2lEPTB;MkSuPFg1PCEQvF2= NHTEenRUSU6JRWK=
Ramos-2G6-4C10 NFu3PI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ4LkS5PFEh|ryP M2f3[XNCVkeHUh?=
DBTRG-05MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nPNWlEPTB;Mk[uOlQ5QCEQvF2= NXi3eFJqW0GQR1XS
NCI-H2052 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG1b25NUUN3ME2yO{42Pjh2IN88US=> NH;VZY5USU6JRWK=
RMG-I M1f1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ7LkSxN|kh|ryP NGLY[pVUSU6JRWK=
H9 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\UcmlEPTB;M{GuN|AxQCEQvF2= M{G3N3NCVkeHUh?=
GR-ST NWP3SJppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN{LkS0OVMh|ryP MlPYV2FPT0WU
Mo-T NET3TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\DeYpKSzVyPUOyMlUxPDZizszN Mm\OV2FPT0WU
SW1088 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWzZmZKSzVyPUOyMlk5ODFizszN MXXTRW5ITVJ?
LB2518-MEL NH;ESWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qwW2lEPTB;M{OuNFc6PyEQvF2= NXr1SnJ5W0GQR1XS
NCI-H82 M3XPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTN|LkG2OlEh|ryP MV3TRW5ITVJ?
LAMA-84 M2HYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln6TWM2OD1|ND62NFc{KM7:TR?= Ml;OV2FPT0WU
KYSE-450 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN2Lk[3O|Yh|ryP NGC3VGdUSU6JRWK=
LU-99A MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK5[ZlKSzVyPUO1MlAxODdizszN NH3JOo1USU6JRWK=
BE-13 NVjLfWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXrcmJKSzVyPUO1MlY2PDVizszN NHHwZohUSU6JRWK=
GAK NXHrd5RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN3Lk[5OUDPxE1? NWjRbpZtW0GQR1XS
NCI-H1573 NHjrTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\rfGZsUUN3ME2zOU45QDF6IN88US=> M1TvUHNCVkeHUh?=
AsPC-1 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfuV5l2UUN3ME2zOk4yPTJ5IN88US=> M1y1RXNCVkeHUh?=
HDLM-2 NVzUZ4tKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP1TVBKSzVyPUO2MlMyPiEQvF2= MXzTRW5ITVJ?
NCI-H441 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTN5LkC2PVEh|ryP NGTqSFJUSU6JRWK=
CAL-27 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnCVnJSUUN3ME2zO{44OjNzIN88US=> MYLTRW5ITVJ?
OVCAR-3 M4TXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTkTWM2OD1|OT6zNVgyKM7:TR?= NXjCbWY5W0GQR1XS
RPMI-8226 NFrYPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTJTWM2OD1|OT61PVgh|ryP NXeyOnRxW0GQR1XS
EFO-21 M1;EeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;oTWM2OD12MD61PFE1KM7:TR?= MUHTRW5ITVJ?
SNU-C2B MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrn[WxLUUN3ME20NU42ODh2IN88US=> MVjTRW5ITVJ?
VM-CUB-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qwWmlEPTB;NEOuPFA{PyEQvF2= Mo\OV2FPT0WU
NCI-H2087 NXT3UFBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqzPW5WUUN3ME20OU4xOjN|IN88US=> MWXTRW5ITVJ?
EW-16 NIO2eGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXGTXJOUUN3ME20Ok4{OTN5IN88US=> MXvTRW5ITVJ?
SK-N-AS NFrjWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPsZo5KSzVyPUS2MlcyPjdizszN MofEV2FPT0WU
COR-L105 NEfZeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR4Lki4OVch|ryP NFfnS3BUSU6JRWK=
DEL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHyTWM2OD12OD6wOFI6KM7:TR?= NWSwPHl6W0GQR1XS
JVM-2 NVHJbphuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfvZ2VKSzVyPUS4MlA2PThizszN M4jxcnNCVkeHUh?=
KARPAS-45 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPWfGNmUUN3ME20PU41PTN6IN88US=> M4DMeXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
体内研究 Nutlin-3α以剂量依赖性方式抑制异种移植物生长,在最高剂量(200毫克/千克)时表现大量的肿瘤收缩。Nutlin-3是p53途径在体内的选择性活化剂,并高度有效地抗SJSA-1骨肉瘤。有野生型p53和MDM2基因扩增的肿瘤对Nutlin-3α治疗应答最好。 [1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[3]
- 合并

Biacore研究:

竞争分析是在Biacore S51进行。甲系列S传感器芯片CM5衍生化用于固定一个PentaHis抗体来捕获His-标记的p53。捕获的水平是〜200响应单位(1单位响应对应于每毫米21 pg的蛋白质)。 MDM2蛋白的浓度被保持恒定在300 nM。将试验化合物溶解于10 mM DMSO中,并进一步稀释使每个MDM2测试样品中的浓度系列抑制剂。该试验是在25¡交流的电泳缓冲液(10 mM HEPES,0.15M的NaCl,2%DMSO)中运行。 MDM2-p53在抑制剂存在下的结合的计算方法是在没有抑制剂的结合的百分比,IC 50是使用微软EXCE计算。
细胞实验:[2]
- 合并
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120小时
  • Method: SRB
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: SJSA-1移植体
  • Dosages: 50, 100, 200 毫克/千克 每天两次
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+55% PEG 300+ddH2O
8mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 581.49
化学式

C30H30Cl2N4O4

CAS号 675576-98-4
储存条件 粉状
溶于溶剂
别名 (-)-Nutlin-3

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • 回答:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

相关Mdm2产品

Tags: 购买Nutlin-3a | Nutlin-3a供应商 | 采购Nutlin-3a | Nutlin-3a价格 | Nutlin-3a生产 | 订购Nutlin-3a | Nutlin-3a代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID